Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Tibotec Pharmaceutical Limited |
---|---|
Information provided by: | Tibotec Pharmaceutical Limited |
ClinicalTrials.gov Identifier: | NCT00081978 |
The purpose of this study is to investigate the ability of TMC125, a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), to lower the amount of virus in your blood when administered twice daily for 48 weeks.
Condition | Intervention | Phase |
---|---|---|
HIV Infection |
Drug: TMC125 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Safety/Efficacy Study |
Official Title: | A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125 in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations |
Enrollment: | 211 |
Study Start Date: | March 2004 |
Study Completion Date: | October 2005 |
TMC125 will be given in addition to a combination of anti-HIV drugs that have been selected specifically for you by your doctor. There are three treatment groups in the study. One group will be given a dosage of TMC125, 400 mg twice daily. Another will be given 800 mg twice daily. The third group, a control arm, will not receive TMC125 (formulation TF035). The safety, tolerability and pharmacokinetics (determinations of the concentration of drug in your blood and its evolution over time) of TMC125 will also be evaluated in this study. Patients who have known resistance to NNRTIs and 3 or more protease inhibitor (PI) mutations may be eligible to participate.
One-hundred-fifty (150) patients will be enrolled into this study. TMC125, 400mg twice daily for 48 weeks; TMC125, 800mg twice daily for 48 weeks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CR006736 |
Study First Received: | April 28, 2004 |
Last Updated: | July 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00081978 History of Changes |
Health Authority: | United States: Food and Drug Administration; Ireland: Irish Agriculture and Food Development Authority |
HIV infection TMC125 Non-nucleoside reverse transcriptase inhibitor, TMC125-C223 |
Virus Diseases Anti-Infective Agents Signs and Symptoms Sexually Transmitted Diseases, Viral Anti-Retroviral Agents HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Antiviral Agents Retroviridae Infections Immunologic Deficiency Syndromes Reverse Transcriptase Inhibitors |
Anti-Infective Agents RNA Virus Infections Sexually Transmitted Diseases, Viral Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Immune System Diseases Acquired Immunodeficiency Syndrome Enzyme Inhibitors Infection Antiviral Agents Pharmacologic Actions |
Immunologic Deficiency Syndromes Reverse Transcriptase Inhibitors Virus Diseases Anti-Retroviral Agents HIV Infections Therapeutic Uses Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections Nucleic Acid Synthesis Inhibitors |